Roche yanks Tecentriq kidney cancer apps in U.S., EU by Carly Helfand Tuesday, November 20, 2018 Roche’s I-O rivals are hurtling toward a showdown in kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.
Pfizer preps for BMS showdown with Bavencio kidney cancer data by Carly Helfand Sunday, October 21, 2018 Pfizer has long been kidney cancer player, but it’s looking to take things up a notch with its latest immunotherapy data.
Big Pharmas slash cancer drug prices again for Chinese insurance by Angus Liu Wednesday, October 10, 2018 Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Pfizer inks $23.8M deal to settle DOJ's kickback probe by Eric Sagonowsky Thursday, May 24, 2018 Targeted by the Justice Department in an industrywide copay assistance investigation, Pfizer has now agreed to a $23.85 million deal with the feds.
Pfizer strikes out on Inlyta expansion bid by Eric Sagonowsky Wednesday, April 11, 2018 Pfizer has been looking to expand Inlyta's use to kidney cancer patients at a high risk of disease recurrence after surgery—but it's fallen short.
Roche's Tecentriq-Avastin pairing bests Sutent in kidney cancer by Tracy Staton Monday, December 11, 2017 With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.
Pfizer’s Sutent approved to prevent recurrence of kidney cancer by Eric Palmer Friday, November 17, 2017 Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.
Pfizer's Sutent expansion snags on tie panel vote by Tracy Staton Thursday, September 21, 2017 Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.
BMS' Opdivo-Yervoy combo slashes kidney cancer death risk by Tracy Staton Sunday, September 10, 2017 A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.
